
India Osteoarthritis Therapeutics Market Report and Forecast 2025-2034
Description
The India osteoarthritis therapeutics market was valued at USD 382.20 Million in 2024, driven by factors such as increasing healthcare awareness, rising osteoarthritis prevalence, and improvements in treatment options across the region. The market is expected to grow at a robust CAGR of 5.40% from 2025 to 2034, with projected values reaching USD 646.69 Million by 2034. This growth reflects the expansion of healthcare infrastructure, advancements in therapeutics, and a growing demand for effective osteoarthritis treatments across the country.
India Osteoarthritis Therapeutics Market Overview
Osteoarthritis therapeutics encompass a range of treatment approaches, including analgesics, nonsteroidal anti-inflammatory drugs, physical therapy, lifestyle modifications, and surgical options, to alleviate joint pain, enhance mobility, and slow disease progression. In India, the osteoarthritis therapeutics market is poised to grow at a CAGR of 5.40% during the forecast period of 2025–2034, due to the increasing elderly population, sedentary lifestyles, obesity, and greater awareness of early diagnosis.
India Osteoarthritis Therapeutics Market Growth Drivers
High Osteoarthritis Prevalence to Accelerate Therapeutics Market Growth in India
A major growth driver in the market in India is the increasing prevalence of osteoarthritis, particularly among the aging and obese population. According to a study published by the National Institutes of Health (NIH) in March 2024, multiple studies across India reported osteoarthritis prevalence rates ranging from 20% to 40%. This significant and growing disease burden is expected to boost demand for effective treatment solutions, thereby driving sustained market expansion in the coming years.
India Osteoarthritis Therapeutics Market Trends
Some of the notable trends include a rising emphasis on non-opioid pain relief for osteoarthritis.
Increasing Focus on Non-Opioid Pain Relief for Osteoarthritis in India
A significant trend in the market is the growing emphasis on non-opioid treatments for pain relief. In April 2025, Sun Pharma and Israel-based Moebius Medical Limited announced the publication of MM-II’s Phase 2b clinical trial results, highlighting the potential of a novel, non-opioid injection to deliver long-lasting pain relief and protect cartilage in osteoarthritis patients. As the market looks for alternatives to traditional treatments, innovations like MM-II are expected to play a crucial role in shaping the future of osteoarthritis management, ultimately contributing to market growth.
India Osteoarthritis Therapeutics Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
NSAIDs to Account for a Significant Share for Segmentation by Drug Classes
The market, based on drug class, is divided into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, other analgesics, hyaluronic acid injections, and others. NSAIDs are expected to dominate due to their proven efficacy in pain and inflammation management. Their accessibility, affordability, and role as a primary line of treatment make them the most utilized drug category in osteoarthritis therapeutics across the Indian pharmaceutical landscape.
Leading Players in the India Osteoarthritis Therapeutics Market
The key features of the market report comprises epidemiology, clinical trials analysis, patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sun Pharmaceutical Industries Ltd.
Headquartered in Mumbai, India, Sun Pharmaceutical Industries Ltd. was established in 1983. The company is actively involved in the osteoarthritis therapeutics market, notably through its MM-II candidate. This treatment has shown promising results in clinical trials, offering durable pain relief for knee osteoarthritis patients. The Phase 2b study demonstrated significant improvements, positioning MM-II as a potential alternative to existing treatments.
Dr. Reddy’s Laboratories
Dr. Reddy's Laboratories, established in 1984 and headquartered in Hyderabad, India, is a leading pharmaceutical company. In the osteoarthritis market, it has launched Hyalosyn, an intra-articular sodium hyaluronate injection aimed at providing relief for knee joint stiffness and immobility. Developed in collaboration with Gland Pharma, Hyalosyn addresses the growing demand for arthritis therapies in India, positioning Dr. Reddy’s as a key contributor to the market.
Cipla Ltd.
Cipla Limited, established in 1935 and headquartered in Mumbai, India, is a leading global pharmaceutical company. It has been actively involved in the India osteoarthritis therapeutics market, received approval for its generic version of Diclofenac sodium topical gel (1%), a therapeutic equivalent to Voltaren gel. This non-steroidal anti-inflammatory drug (NSAID) provides pain relief for osteoarthritis of joints such as the knees and hands, catering to the growing demand in India for affordable treatments.
Zydus Lifesciences Ltd.
Headquartered in Ahmedabad, India, and established in 1952, Zydus Lifesciences Limited has strengthened its presence in the market with the USFDA approval for its Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in February 2025. Indicated for osteoarthritis and rheumatoid arthritis, this formulation helps manage symptoms while reducing gastrointestinal risks. Produced at its Ahmedabad facility, the approval reflects Zydus's expanding therapeutic portfolio and growing global and domestic influence in musculoskeletal treatment solutions.
Other key players in the market include Aurobindo Pharma Ltd., Troikaa Pharmaceuticals Ltd., Meril Life Sciences Pvt. Ltd., and Lupin Ltd.
Key Questions Answered in the India Osteoarthritis Therapeutics Market Report
India Osteoarthritis Therapeutics Market Overview
Osteoarthritis therapeutics encompass a range of treatment approaches, including analgesics, nonsteroidal anti-inflammatory drugs, physical therapy, lifestyle modifications, and surgical options, to alleviate joint pain, enhance mobility, and slow disease progression. In India, the osteoarthritis therapeutics market is poised to grow at a CAGR of 5.40% during the forecast period of 2025–2034, due to the increasing elderly population, sedentary lifestyles, obesity, and greater awareness of early diagnosis.
India Osteoarthritis Therapeutics Market Growth Drivers
High Osteoarthritis Prevalence to Accelerate Therapeutics Market Growth in India
A major growth driver in the market in India is the increasing prevalence of osteoarthritis, particularly among the aging and obese population. According to a study published by the National Institutes of Health (NIH) in March 2024, multiple studies across India reported osteoarthritis prevalence rates ranging from 20% to 40%. This significant and growing disease burden is expected to boost demand for effective treatment solutions, thereby driving sustained market expansion in the coming years.
India Osteoarthritis Therapeutics Market Trends
Some of the notable trends include a rising emphasis on non-opioid pain relief for osteoarthritis.
Increasing Focus on Non-Opioid Pain Relief for Osteoarthritis in India
A significant trend in the market is the growing emphasis on non-opioid treatments for pain relief. In April 2025, Sun Pharma and Israel-based Moebius Medical Limited announced the publication of MM-II’s Phase 2b clinical trial results, highlighting the potential of a novel, non-opioid injection to deliver long-lasting pain relief and protect cartilage in osteoarthritis patients. As the market looks for alternatives to traditional treatments, innovations like MM-II are expected to play a crucial role in shaping the future of osteoarthritis management, ultimately contributing to market growth.
India Osteoarthritis Therapeutics Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Hip Osteoarthritis
- Spinal Osteoarthritis
- Knee Osteoarthritis
- Hand Osteoarthritis
- Others
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Other Analgesics
- Corticosteroids
- Hyaluronic Acid Injections
- Others
- Tablets and Capsules
- Injections
- Creams and Gels
- Others
- Oral
- Parenteral
- Topical
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
NSAIDs to Account for a Significant Share for Segmentation by Drug Classes
The market, based on drug class, is divided into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, other analgesics, hyaluronic acid injections, and others. NSAIDs are expected to dominate due to their proven efficacy in pain and inflammation management. Their accessibility, affordability, and role as a primary line of treatment make them the most utilized drug category in osteoarthritis therapeutics across the Indian pharmaceutical landscape.
Leading Players in the India Osteoarthritis Therapeutics Market
The key features of the market report comprises epidemiology, clinical trials analysis, patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sun Pharmaceutical Industries Ltd.
Headquartered in Mumbai, India, Sun Pharmaceutical Industries Ltd. was established in 1983. The company is actively involved in the osteoarthritis therapeutics market, notably through its MM-II candidate. This treatment has shown promising results in clinical trials, offering durable pain relief for knee osteoarthritis patients. The Phase 2b study demonstrated significant improvements, positioning MM-II as a potential alternative to existing treatments.
Dr. Reddy’s Laboratories
Dr. Reddy's Laboratories, established in 1984 and headquartered in Hyderabad, India, is a leading pharmaceutical company. In the osteoarthritis market, it has launched Hyalosyn, an intra-articular sodium hyaluronate injection aimed at providing relief for knee joint stiffness and immobility. Developed in collaboration with Gland Pharma, Hyalosyn addresses the growing demand for arthritis therapies in India, positioning Dr. Reddy’s as a key contributor to the market.
Cipla Ltd.
Cipla Limited, established in 1935 and headquartered in Mumbai, India, is a leading global pharmaceutical company. It has been actively involved in the India osteoarthritis therapeutics market, received approval for its generic version of Diclofenac sodium topical gel (1%), a therapeutic equivalent to Voltaren gel. This non-steroidal anti-inflammatory drug (NSAID) provides pain relief for osteoarthritis of joints such as the knees and hands, catering to the growing demand in India for affordable treatments.
Zydus Lifesciences Ltd.
Headquartered in Ahmedabad, India, and established in 1952, Zydus Lifesciences Limited has strengthened its presence in the market with the USFDA approval for its Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in February 2025. Indicated for osteoarthritis and rheumatoid arthritis, this formulation helps manage symptoms while reducing gastrointestinal risks. Produced at its Ahmedabad facility, the approval reflects Zydus's expanding therapeutic portfolio and growing global and domestic influence in musculoskeletal treatment solutions.
Other key players in the market include Aurobindo Pharma Ltd., Troikaa Pharmaceuticals Ltd., Meril Life Sciences Pvt. Ltd., and Lupin Ltd.
Key Questions Answered in the India Osteoarthritis Therapeutics Market Report
- What was the India osteoarthritis therapeutics market value in 2024?
- What is the India osteoarthritis therapeutics market forecast outlook for 2025-2034?
- What are the major factors aiding the India osteoarthritis therapeutics market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major India osteoarthritis therapeutics market trends?
- Which type is expected to dominate the market segment?
- Which drug class is projected to lead the market segment?
- Which dosage form is projected to lead the market segment?
- Which route of administration is anticipated to drive the market segment?
- Which end user is anticipated to drive the market segment?
- Which distribution channel is likely to dominate the market segment?
- Who are the key players involved in the India osteoarthritis therapeutics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Osteoarthritis Therapeutics Market Overview
- 3.1 Asia Pacific Osteoarthritis Therapeutics Market
- 3.1.1 Asia Pacific Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 3.1.2 Asia Pacific Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 3.2 India Osteoarthritis Therapeutics Market
- 3.2.1 India Osteoarthritis Therapeutics Market Historical Value (2018-2024)
- 3.2.2 India Osteoarthritis Therapeutics Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Osteoarthritis Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Osteoarthritis Epidemiology Scenario and Forecast
- 7.1 Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence of Osteoarthritis in India
- 7.3 Total Diagnosed Cases of Osteoarthritis in India
- 7.4 Gender-specific Prevalence of Osteoarthritis in India
- 7.5 Age-specific Prevalence of Osteoarthritis in India
- 7.6 Treatment Seeking Rate of Osteoarthritis in India
- 8 India Osteoarthritis Therapeutics Market Landscape
- 8.1 India Osteoarthritis Therapeutics Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 India Osteoarthritis Therapeutics Market: Product Landscape
- 8.2.1 Analysis By Type
- 8.2.2 Analysis By Drug Class
- 8.2.3 Analysis By Dosage Form
- 8.2.4 Analysis By Route of Administration
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Drug Pipeline Analysis
- 10 India Osteoarthritis Therapeutics Market Challenges and Unmet Needs
- 10.1 Treatment Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 India Osteoarthritis Therapeutics Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 India Osteoarthritis Therapeutics Market Segmentation (218-2034)
- 13.1 India Osteoarthritis Therapeutics Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Hip Osteoarthritis
- 13.1.3 Spinal Osteoarthritis
- 13.1.4 Knee Osteoarthritis
- 13.1.5 Hand Osteoarthritis
- 13.1.6 Others
- 13.2 India Osteoarthritis Therapeutics Market (2018-2034) by Drug Class
- 13.2.1 Market Overview
- 13.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 13.2.3 Other Analgesics
- 13.2.4 Corticosteroids
- 13.2.5 Hyaluronic Acid Injections
- 13.2.6 Others
- 13.3 India Osteoarthritis Therapeutics Market (2018-2034) by Dosage Form
- 13.3.1 Market Overview
- 13.3.2 Tablets and Capsules
- 13.3.3 Injections
- 13.3.4 Creams and Gels
- 13.3.5 Others
- 13.4 India Osteoarthritis Therapeutics Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Topical
- 13.5 India Osteoarthritis Therapeutics Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Specialty Clinics
- 13.5.4 Homecare Settings
- 13.5.5 Others
- 13.6 India Osteoarthritis Therapeutics Market (2018-2034) by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Hospital Pharmacies
- 13.6.3 Retail Pharmacies
- 13.6.4 Online Pharmacies
- 14 Regulatory Framework
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Patent Age
- 15.4 Analysis by CPC Analysis
- 15.5 Analysis by Patent Valuation
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Initiatives
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Market Share Analysis (Top 5 Companies)
- 18.2 Sun Pharmaceutical Industries Ltd.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News and Developments
- 18.2.5 Certifications
- 18.3 Dr. Reddy’s Laboratories
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News and Developments
- 18.3.5 Certifications
- 18.4 Cipla Ltd.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News and Developments
- 18.4.5 Certifications
- 18.5 Zydus Lifesciences Ltd.
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News and Developments
- 18.5.5 Certifications
- 18.6 Aurobindo Pharma Ltd.
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News and Developments
- 18.6.5 Certifications
- 18.7 Troikaa Pharmaceuticals Ltd.
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News and Developments
- 18.7.5 Certifications
- 18.8 Meril Life Sciences Pvt. Ltd.
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News and Developments
- 18.8.5 Certifications
- 18.9 Lupin Ltd.
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News and Developments
- 18.9.5 Certifications
- 19 Osteoarthritis Therapeutics Market - Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.